EKOS™ Jena Experience: Safety, Feasibility, and Midterm Outcomes of Percutaneous Ultrasound-Assisted Catheter-Directed Thrombolysis in Patients with Intermediate-High-Risk or High-Risk Pulmonary Embolism
Open Access
- 27 February 2022
- journal article
- research article
- Published by Wiley in Canadian Respiratory Journal
- Vol. 2022, 1-9
Abstract
Background. Percutaneous catheter-based ultrasound-assisted thrombolysis (UACDT) is recommended for patients with intermediate-high-risk or high-risk pulmonary embolism (PE) in whom systemic thrombolysis has failed or is contraindicated. Aim. To evaluate the safety and efficiency of UACDT in patients with intermediate-high-risk or high-risk PE. Methods. Between October 2017 and January 2020, we performed UACDT using the EkoSonic™ Endovascular System (EKOS™) in 51 patients (21 males, age 63 ± 18 years) with a sPESI of 1.3 ± 0.7. The EKOS™-catheter was implanted within 24 h after admission. Over 15 hours, 11.5 mg of alteplase was administered per catheter. We evaluated right ventricular stress and cardiac biomarkers before and after UACDT. Results. 24 h post-UACDT, median RV/LV ratio decreased from 1.13 to 0.96 ( ) and the mean sPAP decreased from 47 ± 3 to 32 ± 2 mmHg + CVP ( ). There were 6 major bleeding events resulting in transfusion. No stroke, myocardial infarction, right heart decompensation, or recurrent PE occurred. 31 patients (63%) were discharged without any signs of right ventricular stress. After at least 3 months, 73% of our patients did not show any signs of right ventricular dysfunction. The mean RV/LV ratio decreased to 0.75 ± 0.03 ( ) in comparison with pre-UACDT, sPAP to 23 mmHg + CVP ( ), and BNP to 40 pg/ml ( ). Conclusions. The treatment with UACDT reduced right heart stress during the first 24 hours and midterm in patients with intermediate-high-risk or high-risk PE at an acceptable rate of severe complications.Keywords
This publication has 28 references indexed in Scilit:
- Fibrinolysis for Patients with Intermediate-Risk Pulmonary EmbolismNew England Journal of Medicine, 2014
- Lower dosage of recombinant tissue-type plasminogen activator (rt-PA) in the treatment of acute pulmonary embolism: A systematic review and meta-analysisThrombosis Research, 2014
- Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary EmbolismCirculation, 2014
- Moderate Pulmonary Embolism Treated With Thrombolysis (from the “MOPETT” Trial)The American Journal of Cardiology, 2013
- Standardized Bleeding Definitions for Cardiovascular Clinical TrialsCirculation, 2011
- Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications. A systematic review and meta‐analysis of the management outcome studiesJournal of Thrombosis and Haemostasis, 2010
- Efficacy and Safety of Low Dose Recombinant Tissue-Type Plasminogen Activator for the Treatment of Acute Pulmonary ThromboembolismChest, 2010
- Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patientsJournal of Thrombosis and Haemostasis, 2009
- Multidetector Computed Tomography for Acute Pulmonary EmbolismNew England Journal of Medicine, 2006
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993